10 Gentium SpA Analyst Ratings, Earnings, Dividends and Insider Trades | $GENT | NASDAQ:GENT | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Gentium SpA Company Profile (NASDAQ:GENT) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Gentium SpA (NASDAQ:GENT) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)Consensus Rating:Buy (Score: 2.50)Consensus Price Target: $58.05 (5.47% upside) Analysts' Ratings History for Gentium SpA (NASDAQ:GENT) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/19/2014ZacksDowngradeOutperform -> Neutral$59.10View 1/2/2014ZacksUpgradeNeutral -> Outperform$59.10View 12/20/2013WedbushDowngradeOutperform -> Neutral$68.00 -> $57.00View 12/2/2013ZacksDowngradeOutperform -> Neutral$55.20View 11/1/2013WedbushBoost Price TargetOutperform$35.00 -> $55.00View 10/22/2013Brean CapitalReiterated RatingBuyView 10/16/2013ZacksUpgradeNeutral -> Outperform$30.50View 10/7/2013ZacksReiterated RatingHold$23.00View 10/7/2013Brean CapitalBoost Price TargetBuy$24.00 -> $38.00View 9/30/2013WedbushBoost Price TargetOutperform$20.00 -> $35.00View 8/29/2013ZacksDowngradeOutperform -> Neutral$23.00View 8/14/2013Brean CapitalBoost Price TargetBuy$21.00 -> $24.00View 7/31/2013ZacksUpgradeNeutral -> Outperform$15.70View 5/29/2013TheStreetUpgradeHold -> BuyView 4/4/2012Brean CapitalInitiated CoverageBuy$16.00View (Data available from 3/8/2012 forward) Earnings History for Gentium SpA (NASDAQ:GENT)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare10/31/2013$0.20$0.22ViewListenView 8/13/2013Q2 2013$0.02$0.16ViewN/AView 5/14/2013Q1 2013$0.00$0.00ViewN/AView 3/28/2013Q4 2012$0.00$0.00ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Gentium SpA (NASDAQ:GENT)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Gentium SpA (NASDAQ:GENT)No insider trades for this company have been tracked by Analyst Ratings Network About Gentium SpA Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a drug based on single-stranded deoxyribonucleic acid (DNA) derived from pig intestines. The Companyâ€™s development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive disease (VOD), a condition, in which some of the veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation treatments, that are given prior to stem cell transplantation. The Company has completed two clinical trials, a Phase III trial of defibrotide for the treatment of severe VOD in the United States, Canada and Israel and a Phase II/III pediatric trial in Europe for the prevention of VOD. Defibrotide has been given orphan status by the United States Food and Drug Agency (FDA), and the European Medicines Agency (EMEA). The Company also manufactures defibrotide and sulglicotide at its manufacturing facility near Como, Italy. Headlines: (2/14) Synthetic Biologics (SYN) Worth Watching: Stock Soars 19.8% (2/14) Strength Seen in Retrophin (RTRX): Stock Soars 49.8% (2/18) Acura Pharmaceuticals, Inc. (ACUR) Looks Good: Stock Adds 5.1% in Session (2/11) Inovio Pharmaceuticals, Inc. (INO) Jumps: Stock Up 6.2% (2/11) Inovio Pharmaceuticals, Inc. (INO) in Focus: Stock Moves 5.1% Higher (2/10) Repros Therapeutics (RPRX) Jumps: Stock Rises 6.1% (2/10) Sunesis (SNSS) Catches Eye: Stock Soars 18.3% (2/14) Cynosure, Inc. (CYNO) Looks Good: Stock Adds 6% in Session Industry, Sector and Symbol: Sector: Healthcare Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: GENT CUSIP: Key Metrics: Previous Close: $55.5650 Day Moving Average: $56.7206200 Day Moving Average: $43.5639 P/E Ratio: 115.51P/E Growth: N/AMarket Cap: $848.9MCurrent Quarter EPS Consensus Estimate: $0.46 EPS Additional Links: View GENT on Google FinanceView GENT on Yahoo FinanceView GENT's Company Profile on ReutersSearch for Gentium SpA on Google Gentium SpA (NASDAQ:GENT) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.